Internal Medicine Alert
RSSArticles
-
Zinc Supplementation: A Risk for Copper Deficiency
Zinc deficiency is frequently misdiagnosed based on a low level without considering albumin concentration and/or an inflammatory state.
-
ECG Review: Sinus Tachycardia with Tall, Peaked T Waves
If told that this patient was having new-onset chest pain we would wonder why his heart rate is so fast, and we would clearly be concerned that the prominent T wave peaking might be ischemic or a DeWinter T wave equivalent.
-
Clinical Briefs
In this issue: flat basal insulin, another possible interventional fix for atrial fibrillation, and a glimmer of hope for beta-blockers in heart failure from diastolic dysfunction.
-
Tedizolid Phosphate Injection and Tablets (Sivextro®)
A new oxazolidinone-class antibacterial has been approved for the treatment of acute bacterial skin and skin structure infections.
-
Prevalence of Rest Tremor in Essential Tremor
Rest tremor is seen in patients with more advanced essential tremor, yet its prevalence varies significantly between patient groups.
-
Is It Time to Purge Full-Strength Aspirin from the Outpatient Armamentarium?
The current study provides further evidence of a lack of benefit to high-dose maintenance aspirin, along with a suggestion of harm.
-
Comparative Efficacy and Safety of Blood Pressure-lowering Agents in Adults with Diabetes and Kidney Disease
Although no blood pressure-lowering strategy prolonged survival in adults with diabetes and kidney disease in this meta-analysis, angiotensin-converting enzyme and angiotensin-receptor blockers, alone or in combination, were the most effective pharmacological strategies to prevent the development of end-stage renal disease.
-
Clinical Briefs
Updates on treatment of depression, the prevention and treatment of osteoporosis, and subclinical thyroid dysfunction as it relates to fracture risk.
-
Pharmacology Update: Memantine HCl and Donepezil HCl Capsules (Namzaric™)
The addition of memantine to a stable dose of an acetylcholinesterase inhibitor may improve cognitive performance.
-
PCSK9: A Major New Advance in Cholesterol-lowering Therapy
When added to statin therapy at the maximum tolerated dose, the PCSK9 inhibitor alirocumab reduced low-density lipoprotein cholesterol levels by 62% and also reduced the rate of occurrence of cardiovascular events.